CTLA4 and neoplasm: Ipilimumab and tremelimumab are mAb formulated to counteract the activity of CTLA-4 (molecule downregulating the activation of T cells through a homeostatic feedback loop) thus allowing the prolonged activation of T cells, restoration of proliferative potentials of T cells to enhance T-cell mediated immunity along with patient’s anti-tumor immune response [30].